Perspective
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression

Susan D. Rountree, Alireza Atri, Oscar L. Lopez and Oscar L. Lopez

Alzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002

Abstract

Background Randomized controlled trials (RCTs) provide safety and efficacy data for regulatory approval of antidementia drugs, but offer limited data regarding real-world effectiveness. Long-term observational controlled studies (LTOCs) extend our understanding by providing longitudinal data across multiple stages of Alzheimer‘s disease (AD). Methods Comparisons of strengths, limitations, evidence level, and results for monotherapy (cholinesterase inhibitors) and combination therapy (cholinesterase inhibitors + memantine) in RCTs versus LTOCs were made. Results Similar to RCTs, LTOCs have shown that both monotherapy and combination therapy are associated with slower cognitive and functional decline. Combination therapy is associated with better cognitive outcomes and greater delays in time to nursing home admission versus monotherapy or no treatment. Persistent antidementia drug treatment is associated with slower decline in cognition, daily function, and global severity, even in patients with advanced disease. Conclusions LTOCs provide complementary evidence regarding effectiveness of antidementia therapy over many years, a time course relevant to AD management. These findings also provide compelling arguments in favor of using LTOCs to estimate effectiveness, risk–benefit, and costs of AD treatments.

ASCI-ID: 285-269

View Fulltext

Similar Articles


A European perspective on population studies of dementia

Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003

Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2

Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002

Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United States

Alzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

Alzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004

The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkers

Alzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumab

Alzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353

Extended results of the Alzheimer‘s disease anti-inflammatory prevention trial

Alzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003

Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementia

Alzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228

Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002

The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotype

Alzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patients

Alzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004

Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus

Alzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008

Long-term progression of Alzheimer‘s disease in patients under antidementia drugs

Alzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009

The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scales

Alzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trials

Alzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005

An economic evaluation of early assessment for Alzheimer‘s disease in the United Kingdom

Alzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001

Modeling Alzheimer‘s disease progression using the disease system analysis approach

Alzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012

Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease

Alzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Alzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004

[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies

Alzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003

An investigation of PreMCI: Subtypes and longitudinal outcomes

Alzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002

Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006

Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008

Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012

Alzheimer‘s disease: Pathogenesis and prevention

Alzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011

The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Alzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005

Safety and biomarker effects of solanezumab in patients with Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224

Leptin and dementia over 32 years–The Prospective Population Study of Women

Alzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411

Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores

Alzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Alzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900

Worldwide Alzheimer‘s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007

Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathology

Alzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408

Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriers

Alzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010

Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative Project

Alzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging

Alzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005

Amyloid imaging in dementias with atypical presentation

Alzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003

Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

Alzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]

Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking

Alzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006

Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testing

Alzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233

A new informant-based questionnaire for instrumental activities of daily living in dementia

Alzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006

Comparison of International Working Group criteria and National Institute on Aging–Alzheimer‘s Association criteria for Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008

Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokers

Alzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231

The worldwide economic impact of dementia 2010

Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006

Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ Study

Alzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disorders

Alzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002

The economics of mild cognitive impairment

Alzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117

Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

Alzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223

Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiology

Alzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005

Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease

Alzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006

Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollment

Alzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001

β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau

Alzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials

Alzheimer`s & Dementia, 2010, 6(5), 367-377. DOI: 10.1016/j.jalz.2010.07.004

Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plans

Alzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006

Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results

Alzheimer`s & Dementia, 2009, 5(2), 93-104. DOI: 10.1016/j.jalz.2008.09.004

Commentary on `A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.` Recruitment of participants for Alzheimer's disease clinical trials: The role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors

Alzheimer`s & Dementia, 2009, 5(2), 122-124. DOI: 10.1016/j.jalz.2009.01.016

Commentary on ”A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.“ Innovations in care that advance Alzheimer's disease drug development

Alzheimer`s & Dementia, 2009, 5(2), 159-162. DOI: 10.1016/j.jalz.2009.01.017

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumab

Alzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trials

Alzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005

Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trials

Alzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005

Improving Alzheimer‘s disease phase II clinical trials

Alzheimer`s & Dementia, 2013, 9(1), 39-49. DOI: 10.1016/j.jalz.2012.02.002